These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 31142380)

  • 1. Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations.
    Chandramohan V; Bao X; Yu X; Parker S; McDowall C; Yu YR; Healy P; Desjardins A; Gunn MD; Gromeier M; Nair SK; Pastan IH; Bigner DD
    J Immunother Cancer; 2019 May; 7(1):142. PubMed ID: 31142380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy.
    Chandramohan V; Bao X; Keir ST; Pegram CN; Szafranski SE; Piao H; Wikstrand CJ; McLendon RE; Kuan CT; Pastan IH; Bigner DD
    Clin Cancer Res; 2013 Sep; 19(17):4717-27. PubMed ID: 23857604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotoxin-αCD40 therapy activates innate and adaptive immunity and generates a durable antitumor response in glioblastoma models.
    Parker S; McDowall C; Sanchez-Perez L; Osorio C; Duncker PC; Briley A; Swartz AM; Herndon JE; Yu YA; McLendon RE; Tedder TF; Desjardins A; Ashley DM; Gunn MD; Enterline DS; Knorr DA; Pastan IH; Nair SK; Bigner DD; Chandramohan V
    Sci Transl Med; 2023 Feb; 15(682):eabn5649. PubMed ID: 36753564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining toll-like receptor agonists with immune checkpoint blockade affects antitumor vaccine efficacy.
    Jeon D; Hill E; Moseman JE; McNeel DG
    J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38702146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors.
    Zalutsky MR; Boskovitz A; Kuan CT; Pegram CN; Ayriss J; Wikstrand CJ; Buckley AF; Lipp ES; Herndon JE; McLendon RE; Bigner DD
    Nucl Med Biol; 2012 Jan; 39(1):23-34. PubMed ID: 21958852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Production and quality control assessment of a GLP-grade immunotoxin, D2C7-(scdsFv)-PE38KDEL, for a phase I/II clinical trial.
    Chandramohan V; Pegram CN; Piao H; Szafranski SE; Kuan CT; Pastan IH; Bigner DD
    Appl Microbiol Biotechnol; 2017 Apr; 101(7):2747-2766. PubMed ID: 28013405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR/EGFRvIII-targeted immunotoxin therapy for the treatment of glioblastomas via convection-enhanced delivery.
    Bao X; Pastan I; Bigner DD; Chandramohan V
    Receptors Clin Investig; 2016; 3(4):. PubMed ID: 28286803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overcoming resistance to αPD-1 of MMR-deficient tumors with high tumor-induced neutrophils levels by combination of αCTLA-4 and αPD-1 blockers.
    Nebot-Bral L; Hollebecque A; Yurchenko AA; de Forceville L; Danjou M; Jouniaux JM; Rosa RCA; Pouvelle C; Aoufouchi S; Vuagnat P; Smolenschi C; Colomba E; Leary A; Marabelle A; Scoazec JY; Cassard L; Nikolaev S; Chaput N; Kannouche P
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35896284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8
    Semmrich M; Marchand JB; Fend L; Rehn M; Remy C; Holmkvist P; Silvestre N; Svensson C; Kleinpeter P; Deforges J; Junghus F; Cleary KL; Bodén M; Mårtensson L; Foloppe J; Teige I; Quéméneur E; Frendéus B
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35058324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities.
    Coutzac C; Adam J; Soularue E; Collins M; Racine A; Mussini C; Boselli L; Kamsukom N; Mateus C; Charrier M; Cassard L; Planchard D; Ribrag V; Fizazi K; Loriot Y; Lepage P; Scoazec JY; Robert C; Carbonnel F; Chaput N
    J Crohns Colitis; 2017 Oct; 11(10):1238-1246. PubMed ID: 28967957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade.
    Chon HJ; Lee WS; Yang H; Kong SJ; Lee NK; Moon ES; Choi J; Han EC; Kim JH; Ahn JB; Kim JH; Kim C
    Clin Cancer Res; 2019 Mar; 25(5):1612-1623. PubMed ID: 30538109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.
    Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-Intensity Focused Ultrasound (HIFU) Triggers Immune Sensitization of Refractory Murine Neuroblastoma to Checkpoint Inhibitor Therapy.
    Eranki A; Srinivasan P; Ries M; Kim A; Lazarski CA; Rossi CT; Khokhlova TD; Wilson E; Knoblach SM; Sharma KV; Wood BJ; Moonen C; Sandler AD; Kim PCW
    Clin Cancer Res; 2020 Mar; 26(5):1152-1161. PubMed ID: 31615935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perioperative Immune Checkpoint Blockade for Muscle-Invasive and Metastatic Bladder Cancer.
    Ramamurthy C; Wheeler KM; Trecarten S; Hassouneh Z; Ji N; Lee Y; Svatek RS; Mukherjee N
    J Cancer Immunol (Wilmington); 2024; 6(1):29-39. PubMed ID: 38784962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma.
    Winograd R; Byrne KT; Evans RA; Odorizzi PM; Meyer AR; Bajor DL; Clendenin C; Stanger BZ; Furth EE; Wherry EJ; Vonderheide RH
    Cancer Immunol Res; 2015 Apr; 3(4):399-411. PubMed ID: 25678581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18.
    Ma Z; Li W; Yoshiya S; Xu Y; Hata M; El-Darawish Y; Markova T; Yamanishi K; Yamanishi H; Tahara H; Tanaka Y; Okamura H
    Clin Cancer Res; 2016 Jun; 22(12):2969-80. PubMed ID: 26755531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss.
    Sampson JH; Choi BD; Sanchez-Perez L; Suryadevara CM; Snyder DJ; Flores CT; Schmittling RJ; Nair SK; Reap EA; Norberg PK; Herndon JE; Kuan CT; Morgan RA; Rosenberg SA; Johnson LA
    Clin Cancer Res; 2014 Feb; 20(4):972-84. PubMed ID: 24352643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFRvⅢ-targeted immunotoxin combined with temozolomide and bispecific antibody for the eradication of established glioblastoma.
    Huang L; He H; Wang K; Ma X; Chen X; Chen W; Wang X; Jiang X; Feng M
    Biomed Pharmacother; 2022 Nov; 155():113659. PubMed ID: 36095959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical toxicity evaluation of a novel immunotoxin, D2C7-(scdsFv)-PE38KDEL, administered via intracerebral convection-enhanced delivery in rats.
    Bao X; Chandramohan V; Reynolds RP; Norton JN; Wetsel WC; Rodriguiz RM; Aryal DK; McLendon RE; Levin ED; Petry NA; Zalutsky MR; Burnett BK; Kuan CT; Pastan IH; Bigner DD
    Invest New Drugs; 2016 Apr; 34(2):149-58. PubMed ID: 26728879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models.
    Puigdelloses M; Garcia-Moure M; Labiano S; Laspidea V; Gonzalez-Huarriz M; Zalacain M; Marrodan L; Martinez-Velez N; De la Nava D; Ausejo I; Hervás-Stubbs S; Herrador G; Chen Z; Hambardzumyan D; Patino Garcia A; Jiang H; Gomez-Manzano C; Fueyo J; Gállego Pérez-Larraya J; Alonso M
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34281988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.